For research use only. Not for therapeutic Use.
K 01-162 (K162) inhibits the fibril formation of Aβ peptides and eliminates their neurotoxicity. K 01-162 binds with Aβ42 peptide with an EC50 value of 80 nM. K 01-162 binds directly to AβO with a KD value of 19 μM. K 01-162 is capable of penetrating the brain and can be used for the research of Alzheimer’s disease[1][2].
K 01-162 (1 μM; 24 h) reduces the level of intracellular AβO[2].
K 01-162 (0.78-50 μM; 5 min) blocks the synaptic binding activity of AβO in mouse hippocampal neurons[2].
K 01-162 (100 μM; intracerebroventricular infusion 0.25 μL/h for 2 weeks) attenuates amyloid load in vivo[2].
| Catalog Number | I004550 |
| CAS Number | 677746-25-7 |
| Synonyms | 7-bromo-N,N-dimethyl-9H-fluoren-2-amine |
| Molecular Formula | C15H14BrN |
| Purity | ≥95% |
| InChI | InChI=1S/C15H14BrN/c1-17(2)13-4-6-15-11(9-13)7-10-8-12(16)3-5-14(10)15/h3-6,8-9H,7H2,1-2H3 |
| InChIKey | KABXKWWJTYSDTD-UHFFFAOYSA-N |
| SMILES | CN(C)C1=CC2=C(C=C1)C3=C(C2)C=C(C=C3)Br |
| Reference | [1]. Li J, et al. Alzheimer’s disease drug candidates stabilize A-β protein native structure by interacting with the hydrophobic core. Biophys J. 2011 Feb 16;100(4):1076-82. [2]. Hong HS, et al. Candidate anti-A beta fluorene compounds selected from analogs of amyloid imaging agents. Neurobiol Aging. 2010 Oct;31(10):1690-9. |
